Purpose: To compare the safety of regadenoson, a selective agonist of A2A adenosine receptors, combined with low-level exercise, between subjects with mild/moderate chronic obstructive pulmonary disease (COPD) and asthma referred for myocardial perfusion imaging (MPI).

Methods: We studied 116 patients, of whom 67 had COPD and 49 asthma (62 % men, mean age 68.3 ± 11.3 years, range 31 - 87 years). Patient demographics, past medical history, medications, clinical symptoms during stress and changes in blood pressure (BP) and heart rate (HR) were evaluated.

Results: Both groups were comparable with regard to hypertension, dyslipidaemia, diabetes and medications with the exception of a higher rate of use of anticholinergics in patients with COPD and of antileukotrienes in asthmatics (58.2 % vs. 28.6 % and 1.5 % vs. 14.3 %, respectively; all p < 0.01). There was a higher incidence of dyspnoea in COPD patients and of headache and feeling hot in asthmatic patients (40.3 % vs. 22.4 %, 6 % vs. 18.4 % and 10.4 % vs. 26.5 %, respectively; all p < 0.05). Although there was no difference in the incidence of other adverse events, we observed a higher frequency in asthmatics of flushing, dry mouth, sweating and fatigue (1.5 % vs. 6.1 %, 14.9 % vs. 24.5 %, 0 % vs. 4.1 % and 37.3 % vs. 49 %, respectively). Adverse events were self-limiting, except in three patients who suffered persistent dyspnoea (2 of 67 COPD patients; 1 of 49 asthma patients) requiring theophylline administration. We observed no significant changes in BP among either group, but there was a tendency towards a higher increase in systolic BP in COPD patients following regadenoson administration (148.3 ± 27.6 vs. 154.6 ± 31.0 mmHg, p = 0.056).

Conclusion: This study showed a good safety profile in our series of COPD and asthma patients undergoing MPI. Regadenoson was well tolerated by all patients, with dyspnoea, headache and feeling hot showing differences between groups.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-013-2493-9DOI Listing

Publication Analysis

Top Keywords

safety regadenoson
8
mild/moderate chronic
8
chronic obstructive
8
obstructive pulmonary
8
pulmonary disease
8
copd asthma
8
patients copd
8
comparative study
4
study safety
4
regadenoson patients
4

Similar Publications

Article Synopsis
  • - Regadenoson is a selective A2A adenosine receptor agonist used for heart stress testing, and this study evaluates its safety for myocardial perfusion scans.
  • - The study included 63 adult patients, primarily male with an average age of about 57, and looked at their health data and any adverse reactions after using Regadenoson during the testing process.
  • - Results showed minor blood pressure drops that stabilized after an hour, with few non-serious side effects like shortness of breath and headaches, but no major health complications arose.
View Article and Find Full Text PDF

Aim: To assess the radiopharmacist's role in a multidisciplinary team focused on the contraindications of regadenoson in order to ensure the safe use of pharmacologic vasodilator stress agents in patients undergoing SPECT-MPI.

Methods: We ambispectively studied its safe use in 1905 patients (54.1% female, mean age: 66.

View Article and Find Full Text PDF

Regadenoson for the treatment of COVID-19: A five case clinical series and mouse studies.

PLoS One

August 2023

Department of Surgery, Division of Thoracic, University of Maryland, Baltimore, Maryland, United States of America.

Background: Adenosine inhibits the activation of most immune cells and platelets. Selective adenosine A2A receptor (A2AR) agonists such as regadenoson (RA) reduce inflammation in most tissues, including lungs injured by hypoxia, ischemia, transplantation, or sickle cell anemia, principally by suppressing the activation of invariant natural killer T (iNKT) cells. The anti-inflammatory effects of RA are magnified in injured tissues due to induction in immune cells of A2ARs and ecto-enzymes CD39 and CD73 that convert ATP to adenosine in the extracellular space.

View Article and Find Full Text PDF

Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR.

Int J Cardiovasc Imaging

September 2023

Department of Radiology, Clínica Universidad de Navarra, Pamplona, Spain.

Owing to its pharmacodynamics and posology, the use of regadenoson for stress cardiac magnetic resonance (CMR) has potential advantages over other vasodilators. We sought to evaluate the safety, hemodynamic response and diagnostic performance of regadenoson stress-CMR in routine clinical practice. All regadenoson stress-CMR examinations performed between May 2017 and July 2020 at our institution were retrospectively reviewed.

View Article and Find Full Text PDF

Objectives: The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). The study compared the frequency of the side effects of regadenoson and dipyridamole during a SPECT MPI.

Methods: This retrospective study included data of 283 consecutive patients who underwent pharmacological stress tests in years 2015-2020.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!